One of the major challenges in managing the treatment of colorectal cancer (CRC) patients is to predict risk scores or level of risk for CRC patients. In past, several biomarkers, based on concentration of proteins involved in type-2/intrinsic/mitochondrial apoptotic pathway, have been identified for prognosis of colorectal cancer patients. Recently, a prognostic tool DR MOMP has been developed that can discriminate high and low risk CRC patients with reasonably high accuracy (Hazard Ratio, HR = 5.24 and p-value = 0.0031). This prognostic tool showed an accuracy of 59.7% when used to predict favorable/unfavorable survival outcomes. In this study, we developed knowledge based models for predicting risk scores of CRC patients. Models were trained and evaluated on 134 stage III CRC patients. Firstly, we developed multiple linear regression based models using different techniques and achieved a maximum HR value of 6.34 with p-value = 0.0032 for a model developed using LassoLars technique. Secondly, models were developed using a parameter optimization technique and achieved a maximum HR value of 38.13 with p-value 0.0006. We also predicted favorable/unfavorable survival outcomes and achieved maximum prediction accuracy value of 71.64%. The performance of our models were evaluated using five-fold cross-validation technique. For providing service to the community we also developed a web server 'CRCRpred', to predict risk scores of CRC patients, which is freely available at https://webs.iiitd.edu.in/raghava/crcrpred.
Introduction

1
North America, and the least rates in Africa and South-Central Asia [1] . These 13 geographic contrasts seem, by all accounts, to be inferable from the disparity in dietary 14 and ecological exposures that are forced upon a background of genetically determined 15 susceptibility. While, environmental factors (such as lifestyle, diet, physical activity, 16 etc.) have been reported to play an important role [3, 4] , several genetic/epigenetic 17 changes have been elucidated to cause/promote CRC in the past decades [5] . A 18 significant number of biological experiments along with several 19 theoretical/bioinformatics studies based on genomics/proteomics data have revealed a 20 crucial role of the mitochondrial apoptotic pathway in tumor progression [6, 7] . 21 Mitochondrial or apoptotic type 2 signaling pathway is a conserved pathway in many 22 organisms, which controls the lifespans of cells in different tissues and leads to cellular 23 death or apoptosis as a result of genotoxic and other stresses [8] . Alteration in the 24 expression of signaling proteins involved in this pathway has been associated with tumor 25 survival/progression and chemo-resistance development [6, 7] . Apoptotic type 2 26 (intrinsic) pathway consists of a cascade of Bcl2 family proteins which are broadly 27 classified into two categories: Anti-apoptotic proteins that include Bcl2, BclXL, Mcl1 28 and pro-apoptotic proteins that include Bax, Bak, Bid, Bim [9] . Each of these has a 29 definite functional role in regulating the process of mitochondrial pore formation
30
(Mitochondrial Outer Membrane Permeabilization) leading to activation of caspases and 31 ultimately, the demise of the cell [8] (Fig 1) . While anti-apoptotic proteins are agonists 32 to effector pro-apoptotic proteins (such as Bak/Bax), BH3 only activator pro-apoptotic 33 proteins such as Bid, Bim etc. can either cleave Bax/Bak to their active counterparts 34 (exposed TM domains) which further oligomerize on mitochondrial membrane to form This biological understanding has resulted in the design and development of several 40 therapeutic strategies (and drugs) which target Bcl2 family proteins and exploit the 41 mitochondrial pathway to induce apoptosis in tumor cells. Although, it has been 42 observed that the failure rate of these chemotherapeutic drugs (due to tumor relapses) 43 is significant, possibly due to variation in protein expressions [9] and/or variation in 44 ligand-receptor binding affinities amongst proteins (due to mutations) within CRC 45 patients [11, 12] . In 2013, a systems based model DR MOMP was introduced which 46 incorporated concentration data of pro-and anti-apoptotic proteins to predict minimal 47 dose response (BH3 only stress) required for MOMP, which was denoted as η. The 48 authors in this study demonstrated that η can be used to classify a group of 26 CRC 49 patients into responders (favorable outcomes) and non-responders (unfavorable 50 outcomes) to chemotherapy [13] . Recently, application of model DR MOMP has been 51 shown in classification of 134 chemotherapy-treated stage III CRC patients into high 52 and low risk groups. It was observed that high risk patients classified by DR MOMP 53 had around five-fold increased risk of death (HR=5.2, p-value=0.02) as compared to low 54 risk patients [14] . It was successful in differentiation of high and low risk patients with 55 an overall accuracy of 59.7%.
In this study, we made a systematic attempt to develop models for predicting risk 57 score for CRC patients, which can be used to discriminate high and low risk patients. In 58 contrast to DR MOMP, our models are data-driven where parameters are optimised 59 from the protein concentration obtained from CRC patients. In order to evaluate 60 performance of our models, we compute performance in terms of standard parameters 61 such as Hazard ratio (HR) and Confidence Interval (CI). It is important to compare 62 performance of models developed in this study using previously developed models such 63 as DR MOMP. One of the objective of this study is to provide service to society, thus a 64 web server, 'CRCRpred' (https://webs.iiitd.edu.in/raghava/crcrpred) has been 65 developed that can predict risk score for CRC patients.
66
Materials and methods
67
Dataset
68
The dataset 'CRC stage III cohort' used in this study was obtained from [14] 
The dataset corresponding to 134 stage III CRC patients was uniformly divided into 5 114 subsets. A parallel parameter (W) search upto one decimal digit precision was 115 performed iteratively, in order to maximize the objective 'Hazard Ratio' at mean and 116 median cutoffs, on five training sets (each train set ∼ 4 out of 5 subsets). Running five 117 search algorithms parallely with reduced yet homogeneous data saved computation time. 118 The top parameter set obtained for each case (W1,W2,...W5) was then used to evaluate 119 β i and estimate HR values on the complete dataset using mean and median cutoffs. where i = 1,2,...5. From this point onwards we will refer the z-normalized version of the 123 vector β * as Risk Score (RS), for reasons that will become clear later. 
124
Results
125
Single variable based classification
126
Following the univariate analysis presented in [14] , we stratified high and low risk 127 patients on the basis of various factors at median cutoff. The results in Table 1 were tried in an iterative manner to obtain best weights. By means of this method, Risk 171 Score (RS) is predicted that is derived from anti and pro-apoptotic protein levels.
172
In parameter optimization technique, parameters or weights are optimized using 173 iterative techniques which increases the possibility of over optimization. In order to 174 avoid any over optimization, we used the concept of five-fold cross validation (Fig 2) .
175
Results corresponding to different parameter sets W1,W2...W5 and W* are given in 176 stratifying CRC patients, due to their high weights (contribution) in β * . These results 183 also correlate with isolated studies on BclXL and Mcl1 which showed their relevance as 184 prognostic markers in the past [16, 17] . However, a biomarker such as RS accounts for a 185 more comprehensive apoptotic profile and it makes more sense to use it as compared to 186 any single protein. Other factors like age [18] , gender [18] , TNM staging [19] , lymphovascular invasion [20] 213 and location of tumor in colon [21] have been shown to affect colorectal cancer incidence 214 with preferable bias towards certain groups for e.g. incidence rates have been shown to 215 be greater in males than females [18] . Based on these and the results from multivariate 216 analysis, we looked at different sub-populations with a certain clinical/pathological 217 feature in common. Using RS at mean and median cutoffs, we were able to stratify 218 these sub-populations in CRC dataset into high risk and low risk groups. Results in the 219 form of Kaplan Meier plots and logrank tests in Fig 7, show significant stratification of 220 literature-established high risk sub-groups such as patients with older age [18] , patients 221 with tumor located in the right side (right tumor location [21] ), patients with positive 222 lymphovascular invasion [20] , male patients [18] , patients with tumor spread into lymph 223 nodes [19] and patients with larger tumor sizes [19] into further high and low risk 224 patients. Results for other subgroups and median cutoffs are given in Supplementary S1 225 File. 
Web-server for risk prediction in CRC patients: CRCRpred
227
We also developed a web-server CRCRpred, which is freely available at 228 https://webs.iiitd.edu.in/raghava/crcrpred, in order to provide service to the 229 community. This web-server implements the current study in order to predict high and 230 low risk patients given the nanomolar concentration of required Bcl2 family protein(s). 231 Following are the two prediction modules with their brief descriptions:
Often the user will not possess the concentrations of all required Bcl2 family proteins, 234 mainly because protein level quantification is a challenging task in itself. Keeping this 235 in mind we provide this module to the user where, with the limited knowledge of 236 concentration(s) of one or more than one proteins, the risk can be predicted. The BclXL alone) to identify high/low risk CRC cases might not be a good way to solve this 264 problem. We make this evident here by performing a two variable t-test between protein 265 concentrations in favorable and unfavorable patient cases, which showed significant 266 difference in Bak, Bax, BclXL and Mcl1 levels. However, it is for certain that the death 267 pathway is defunct and there exists an unexploited relationship between the overall 268 protein profile and survival of the cancer patient.
269
To tackle this, we first took at the total pro-and anti-apoptotic protein 270 concentration, since both of these are upregulated in the event of cellular stress 271 conditions such as tumor [10] , and stratified the patients on the basis of mean and 272 median cutoffs of this total sum. We also took the difference in the levels of these and 273 repeated the same procedure. While, the former was able to differentiate high and low 274 risk CRC patients effectively (HR value higher than DR MOMP), the latter resulted in 275 an insignificant p-value at median cutoff. Next, we constructed multi variable linear 276 regression models using five-fold cross validation and implementing various techniques. 277 The predicted OS from one of these techniques (LassoLars) was found to stratify high 278 and low risk patients with a high HR, but still performed poorly in comparison to BclXL 279 alone. We then analysed linear combinations of Bcl2 family proteins by making use of a 280 five-fold parameter optimization technique and constructed a parameter Risk Score (RS) 281 which is a remnant of altered protein profile (including paralogs) and/or binding 282 affinities. We found that RS outperforms the task of risk stratification as compared to 283 previous studies as evident on emphasizing the significant differences between the two classified groups for each of 302 these features. It should be noted that these sub-groups are claimed to be prone to high 303 risk of death by previous studies and surveys [18] [19] [20] [21] . A prognostic marker which could 304 classify patients among these sub-groups could be very beneficial for deciding the fate of 305 the patients and future therapy. RS could be one such candidate marker.
306
To provide valuable help to scientific community, a web server, CRCRpred, Table 7 . 
